Gilead Sciences (NASDAQ:GILD) saw its stock decline 2.7% in pre-market trading Thursday following news that CVS Health ...

What Happened? Shares of biopharmaceutical company Gilead Sciences (NASDAQ:GILD) fell 3.5% in the morning session after reports that CVS Health will not be adding the company's new HIV prevention drug ...

CVS Health will not add Gilead Sciences' new HIV prevention drug to its commercial plans for now, despite the medicine's proven effectiveness ...

Is August too early to get this year’s influenza vaccine? Here’s when and where flu shots are available and when the CDC recommends getting one.

On Tuesday, Federal Court Judge Mitchell Goldberg issued a ruling that is the second staggering decision against Woonsocket-based CVS in recent weeks. Whistleblowers brought the two cases alleging ...

Caremark was found liable in June, and Philadelphia federal court Chief Judge Mitchell Goldberg ordered the company to pay ...

Over the past year, activist investors have increased their influence in the healthcare sector, targeting companies like Medtronic, Pfizer, and CVS Health to advocate for enhanced performance and ...

Pharmacy Benefits Manager Express Scripts has filed a motion to move its ongoing class-action lawsuit out of the Cambria ...

Hull CVS, in partnership with The Love Button Global Movement, the charitable arm of Coldplay, celebrated with 180 local ...

A federal judge has ordered CVS Caremark to pay nearly $290 million in damages after determining the pharmacy benefit manager overbilled Medicare for prescription drugs, according to court documents ...

Investing.com -- CVS Health (NYSE: CVS) will not include Gilead Sciences (NASDAQ: GILD )’ new HIV prevention drug Yeztugo in its commercial plans for the time being, despite the medication’s proven ...